Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research
Professor, Psychiatry and Molecular Medicine, The Hofstra North Shore-LIJ School of Medicine
Phone: (718) 470-8126
Dr. Lencz leads the Laboratory of Analytic Genomics within the Center for Psychiatric Neuroscience at The Feinstein Institute for Medical Research. He is founder and co-leader of The Ashkenazi Genome Consortium, an international collaboration of leading researchers studying the genetics of complex disease (ranging from cancer to mental illness to diabetes) by examining DNA samples drawn from members of this genetically unique “founder” population. Dr. Lencz also leads COGENT, the international cognitive genomics consortium, and is a member of the Psychiatric Genomics Consortium.
Dr. Lencz was among the first recipients of the EUREKA (Exceptional, Unconventional Research Enabling Knowledge Acceleration) award from the National Institute of Mental Health, and has previously received a Career Development Award from NIMH and a Young Investigator Award from NARSAD.
Dr. Lencz is the author or co-author of more than 150 peer-reviewed publications of scientific and biomedical literature. He was an invited contributor to the Encyclopedia of Genetics, and has authored numerous book chapters and invited commentaries. Dr. Lencz received his BA from Yale University and his PhD from the University of Southern California.
Dr. Lencz’s primary research focus is the use of biomarkers, especially novel genetic technologies, to refine our understanding of the causes and treatment of schizophrenia.
The Laboratory for Analytic Genomics develops and implements strategies for identifying relationships between genetic variation and psychiatric disease. State-of-the-art molecular technologies, including genome-wide association studies (GWAS) and next-generation sequencing (NGS) platforms, produce a flood of data capturing variation across the entire genome. To manage this unprecedented flow of information, novel analytic methods are required to separate signal from noise.
Dr. Lencz has a particular interest in the development of biomarkers to predict symptom and side effect responses to antipsychotic medications. Dr. Lencz’s team also works closely with members of the Psychiatric Neuroscience department to examine the role that schizophrenia risk genes play in brain structure, function and development.
Yale University, New Haven, CT
Field of Study: Psychology
University of Southern California
Field of Study: Clinical Psychology
University of Southern California
Field of Study: Clinical Psychology
Degree: Postdoctoral Fellowship
Field of Study: Clinical Neurosciences
1989 Yale University: Graduated magna cum laude, 1989; Awarded Distinction in the Major (Psychology)
1990-1993 University of Southern California: University Merit Fellowship
1993 Young Investigator’s Award, International Congress on Schizophrenia Research
1993-1994 Dissertation Fellowship
1993-1994 Predoctoral Fellowship Award, National Institute of Mental Health (NRSA program)
1995 Distinguished Dissertation Award
1996 Hillside Hospital Young Investigator’s Award
2001 NARSAD Young Investigator’s Award
2002 ISI “Hot Paper” Designation (Subfield: Psychiatry/Psychology; for Raine, Lencz et al. 2000)
2003 ACNP Memorial Travel Award
2005 KeySpan Research Fellowship
2007 American Psychopathological Association Robins/Guze Award
2008 NIH EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) Award
2009 Elected Associate Member of the American College of Neuropsychopharmacology
2011 Chair, NIH Member Conflict Panel (Chronic Diseases)
2014 Elected Member of the American College of Neuropsychopharmacology
2015 Chair, NIMH Special Emphasis Panel (RFA-MH-15-400)
2015 Chair, NIMH Special Emphasis Panel (RFA-MH-16-300/310)
- Zhang J-P, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T. (2015) “Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis.” Schizophrenia Bulletin, 41(6):1248-55.
- Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt K, John M, Weissman N, Gallego JA, Kane JM, , Lencz T*, Malhotra AK*. (2015) “Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment.” American Journal of Psychiatry. 2015 Aug 28. [Epub ahead of print] *contributed equally (co-senior authors)
- Trampush JW, Lencz T, Knowles E, Davies G, Guha S, Pe’er I, Liewald DC, Starr JM, Djurovic S, Melle I, Sundet K, Christoforou A, Reinvang I, Mukherjee S, DeRosse P, Lundervold A, Steen VM, John M, Espeseth T, Räikkönen K, Widen E, Palotie A, Eriksson JG, Giegling I, Konte B, Ikeda M, Roussos P, Giakoumaki S, Burdick KE, Payton A, Ollier W, Horan M, Scult M, Dickinson D, Straub RE, Donohoe G, Morris D, Corvin A, Gill M, Hariri A, Weinberger DR, Pendleton N, Iwata N, Darvasi A, Bitsios P, Rujescu D, Lahti J, Le Hellard S, Keller MC, Andreassen OA, Deary IJ, Glahn DC, Malhotra AK. (2015) “Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment.” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 168(5):363-73.
- Lencz T, Malhotra AK. (2015) “Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.” Molecular Psychiatry, 20(7):820-6.
- Carmi S, Hui KY, Kochav E, Liu X, Xue J, Grady F, Guha S, Upadhyay K, Ben-Avraham D, Mukherjee S, Bowen BM, Thomas T, Vijai J, Cruts M, Froyen G, Lambrechts D, Plaisance S, Van Broeckhoven C, Van Damme P, Van Marck H, Barzilai N, Darvasi A, Offit K, Bressman S, Ozelius LJ, Peter I, Cho JH, Ostrer H, Atzmon G, Clark LN, Lencz T*, Pe’er I*. (2014) “Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins.” Nature Communications, 5:4835.*joint corresponding authors
- Mukherjee S, Guha S, Ikeda M, Iwata N, Malhotra AK, Pe’er I, Darvasi A, Lencz T. (2014) “Excess of homozygosity in the major histocompatibility complex in schizophrenia.” Human Molecular Genetics, 23(22):6088-95.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) “Biological insights from 108 schizophrenia-associated genetic loci.” Nature, 511:421–427.
- Lencz T, Knowles E, Davies G, Guha S, Liewald DC, Starr JM, Djurovic S, Melle I, Sundet K, Christoforou A, Reinvang I, Mukherjee S, Lundervold A, Steen VM, John M, Thomas Espeseth, Räikkönen K, Widen E, Palotie A, Eriksson JG, Giegling I, Konte B, Ikeda M, Roussos P, Giakoumaki S, Burdick KE, Payton A, Ollier W, Horan M, Donohoe G, Morris D, Corvin A, Gill M, Pendleton N, Iwata N, Darvasi A, Bitsios P, Rujescu D, Lahti J, Le Hellard S, Keller MC, Andreassen OA, Deary IJ, Glahn DC, Malhotra AK. (2014) “Molecular evidence for genetic overlap between general cognitive ability and risk for schizophrenia: A report from the Cognitive Genomics Consortium (COGENT).” Molecular Psychiatry, 19(2), 168-74.
- Lencz T, Guha S, Liu C, Rosenfeld J, Mukherjee S, DeRosseP, John M, Cheng L, Zhang C, Badner JA, Ikeda M, Iwata N, Cichon S, Rietschel M, Nöthen MM, Cheng ATA, Hodgkinson C, Yuan Q, Kane JM, Lee AT, Pisanté A, Gregersen PK, Pe’er I, Malhotra AK, Goldman D, Darvasi A. (2013) “Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder.” Nature Communications, 4:2739.
- Guha S, Rees E, Darvasi A, Ivanov D, Ikeda M, Bergen SE, Magnusson PK, Cormican P, Morris D, Gill M, Cichon S, Rosenfeld JA, Lee A, Gregersen PK, Kane JM, Malhotra AK, Rietschel M, Nöthen MM, Degenhardt F, Priebe L, Breuer R, Strohmaier J, Ruderfer DM, Moran JL, Chambert KD, Sanders AR, Shi J, Molecular Genetics of Schizophrenia Consortium, Wellcome Trust Case Control Consortium 2, Kendler K, Riley B, O’Neill T, Walsh D, Malhotra D, Corvin A, Purcell S, Sebat J, McCarthy S, Gejman PV, Levinson DF, Owen MJ, O’Donovan MC, Lencz T**, Kirov G**. (2013) “A rare deletion at distal 16p11.2 is implicated in schizophrenia.” JAMA Psychiatry, 70(3):253-60. *corresponding authors contributed equally.